Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030
Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects under the French government’s France 2030 initiative.
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced that it has secured €9.3 million in state funding under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance.
Founded in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with the ambition to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases.
Egle Therapeutics has developed a proprietary translational platform to identify novel tumor-infiltrating Treg targets, with the aim of developing antibody-based candidate drugs to disable Treg function and restore an effective antitumor immune response.
In June 2020, Egle Therapeutics entered a strategic partnership with Takeda Pharmaceuticals, establishing a three-year research collaboration with an option agreement. Since its inception, the company has successfully raised nearly €56 million through equity financing and non-dilutive public funding, including the i-Lab Innovation Competition and DeepTech Development Grant.
During its Series A financing round in October 2021, the company raised €47 million, attracting renowned investors, including EQT Life Sciences, Bpifrance (INNOBIO 2 and Innovation 1), Fund Plus, Bioqube Factory Fund, T1D Fund, and Takeda Ventures.
In 2024, Egle Therapeutics achieved key milestones, including the launch of its Phase I/II clinical trial for EGL-001, the appointment of Michel Detheux as Chairman, and the appointment of Christophe Quéva as Chief Executive Officer.
“We are honored to receive this funding from the French government through France 2030. This recognition and immense support will help Egle Therapeutics advance its research and development programs in regulatory T cell modulation. The funding granted under the ‘Innovations in Biotherapies and Bioproduction’ call for projects will enable us to accelerate the development of EGL-001, our lead immuno-oncology therapeutic candidate. EGL-001 is currently being evaluated in a Phase I/II clinical trial in France and Spain.”
Christophe Quéva, CEO of Egle Therapeutics
About Egle Therapeutics
Egle Therapeutics is a biotechnology company specializing in the development of immunotherapies targeting regulatory T cells. Through its proprietary discovery platform, Egle identifies novel Treg-specific targets and develops innovative Treg-targeting therapeutic candidates for the treatment of cancer and autoimmune diseases.
Egle Therapeutics’ lead immuno-oncology candidate, EGL-001, is currently being evaluated in a Phase I/II clinical trial. In autoimmunity, the company has completed the regulatory studies and manufacturing for a CTA filing for EGL-003 and is preparing to launch a clinical trial in 2025.
For more information www.egle-tx.com
About France 2030
✔ A dual ambition: France 2030 aims to transform key economic sectors (such as healthcare, energy, automotive, aerospace, and space industries) through technological innovation while positioning France not just as a participant but as a global leader in tomorrow’s world. From fundamental research to idea generation, product development, and industrialization, France 2030 supports the entire innovation lifecycle.
✔ Unprecedented scale: France 2030 will invest €54 billion to help French companies, universities, and research institutions navigate ecological and economic transitions, ensuring they remain competitive and emerge as leaders in strategic industries. France 2030 commits to allocating 50% of its funding to decarbonization and 50% to emerging innovators, while adhering to sustainable investment principles (Do No Significant Harm).
✔ Collaborative implementation: Designed and deployed in consultation with economic, academic, local, and European stakeholders, France 2030 determines its strategic priorities through an open, competitive, and selective project application process. Selected projects receive state support to drive innovation and industrial growth.
✔ Led by the General Secretariat for Investment, on behalf of the Prime Minister, France 2030 is implemented by ADEME (Agency for Ecological Transition), ANR (National Research Agency), Bpifrance, and Banque des Territoires.
For more information: france2030.gouv.fr | @SGPI_avenir
About the Call for Projects “Innovations in Biotherapies and Bioproduction”
The call for projects “Innovations in Biotherapies and Bioproduction” is a funding initiative within the France 2030 strategy, specifically under the “Biotherapies and Bioproduction of Innovative Therapies” acceleration plan. Led by the Health Innovation Agency within the Secretariat General for Investment, the program supports excellence in biotherapy research by accelerating technology transfer and ensuring a continuous pipeline of innovations from bench to bedside.
About Bpifrance
Bpifrance provides funding solutions to businesses at every stage of their development, including loans, guarantees, and equity investment. Bpifrance also supports innovation and international expansion through offers a wide range of export financing solutions.
Additionally, Bpifrance provides advisory services, networking opportunities, and business acceleration programs for startups, small- and mid-sized enterprises. With 50 regional offices, Bpifrance ensures entrepreneurs receive close and effective support to tackle their challenges.
For more information: www.bpifrance.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317147647/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group to Announce Full Year 2024 Financial Results on March 28, 202518.3.2025 12:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical”, or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced that it will report its full year 2024 financial results before the U.S. market open on Friday, March 28, 2025. The Company will hold a conference call on Friday, March 28, 2025 at 8:00 am Eastern Time (or Friday, March 28, 2025 at 9:00 pm Japan Time) to discuss the financial results and take questions live. Please register in advance of the conference using the link provided below. It will automatically direct you to the registration page of "SBC 2024 Full Year Financial Results Briefing". Please follow the steps to enter your registration details, then click "Submit". Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as past inve
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression18.3.2025 11:30:00 CET | Press release
Highlights:52-week observational follow-up study from Phase 2b reveals single 25 mg COMP360 psilocybin dose offers longer-term antidepressant effects compared to lower doses, with average efficacy for a single dose of 25mg lasting about 12 weeks and substantially longer in a subgroupFindings published in the March edition of the Journal of Clinical Psychiatry Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the publication of results from the COMP004 study, an observational 52-week follow-up from the Phase 2 COMP001 and COMP003 trials of COMP360 psilocybin treatment in patients with treatment-resistant depression (TRD). The COMP004 study's findings suggest that over a 52-week period, a single administration of 25 mg COMP360 psilocybin demonstrated a longer maintenance of antidepressant effects compared to the 1 mg and 10 mg doses. The results of COMP004 build upon previous findings from t
Pole Vault Star Armand “Mondo” Duplantis Sets His Sights on Fairy Tale World Record of 6.40m18.3.2025 11:08:00 CET | Press release
“6.40 metres is achievable in the next few years” Pole vault world-record holder Armand “Mondo” Duplantis believes he can push the pole-vault world record to 6.40 metres in the next few years, the athlete said in a conversation with PUMA CEO Arne Freundt, which was released as a part of the sports company’s annual report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318752992/en/ When it comes to pole vaulting, Mondo is in a league of his own, having won two Olympic gold medals, two world championships, breaking the world record 11 times and being crowned World Athlete of the Year twice. Even though he just set the world record to 6.27 metres earlier this year, the Swedish athlete has his sights on raising the bar to 6.40 metres in the future. “I think that 6.30 metres is probably the target in the near future, and 6.40 metres is achievable in the next few years,” Mondo said. He said improvements in the technology of hi
Pesto Barilla Presents Accademia del Basilico: The New Education Program for Basil Farmers18.3.2025 11:00:00 CET | Press release
As basil sowing begins, Barilla launches Accademia del Basilico, a training program specifically designed to empower farmers and teach techniques and practices for sustainable basil cultivation. With demand for pesto rising globally, the pesto market experienced a 17% growth in volume from 2023 to 2024 1, Barilla places its hero ingredient, basil, at the heart of its sustainability story. Crafted from a 100% Italian basil supply chain, Pesto Barilla is produced with sustainably farmed basil, which is ISCC Plus certified as part of the Barilla Basil Charter, a set of guidelines verified by RINA (independent third party). This concept of sustainability is further strengthened by the new Accademia del Basilico. In collaboration with DINAMICA, an organization specialized in agri-food training with the support of Open Fields Srl, Barilla has developed this comprehensive program, launched in January 2025, consisting of seven lessons aimed at enhancing farming practices across the basil suppl
Res Integra and Ohmium Will Deploy Four-Megawatt Green Hydrogen Project in Sicily18.3.2025 11:00:00 CET | Press release
Advanced PEM Electrolyzers to Decarbonize Petroleum Refinery and Mobility Res Integra is installing an electrolyzer system with an annual capacity of up to 700 tonnes of hydrogen using Ohmium International PEM electrolyzer technology at a facility in an industrial area of Siracusa (Sicily region, Italy), one of the largest petrochemical sites in Europe. The Ohmium green hydrogen PEM solution is targeted for shipment to commence in 2025; the project will be powered by solar PV, producing green hydrogen to support efforts to decarbonize regional industrial operations and mobility. “I’m glad that Res Integra, part of Irem Group, in collaboration with Ohmium International, for the PEM Electrolyzer supply, is realizing this Hydrogen Project. This leads us towards the construction of green energy plants in line with the objectives of the European economic community,” said Giovanni Musso, CEO of Irem. “We sought advanced electrolyzer technology that was efficient, cost-effective, and quick to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom